Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMSC01 in Acute Myocardial Infarction
NCT04056819Phase 1Completed
- Sponsor
- Ever Supreme Bio-Technology
- Start
- May 2019
- Primary completion
- Aug 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of human umbilical cord derived mesenchymal stem cells in ST elevation myocardial infarction (STEMI), sponsored by Ever Supreme Bio-Technology. Primary endpoints: Treatment Emergent Adverse Events at 12 months, Serious Adverse Events at 12 months and 1 more. Started May 2019; status: completed.
02
Drugs
human umbilical cord derived mesenchymal stem cells
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT04056819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04056819.